Metastatic prostate cancer men’s attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER) : protocol for a prospective, multicentre discrete choice experiment study by Connor, Martin John et al.
1Connor MJ, et al. BMJ Open 2021;11:e048996. doi:10.1136/bmjopen-2021-048996
Open access 
Metastatic prostate cancer men’s 
attitudes towards treatment of the local 
tumour and metastasis evaluative 
research (IP5- MATTER): protocol for a 
prospective, multicentre discrete choice 
experiment study
Martin John Connor   ,1,2 Mesfin G Genie   ,3,4 Michael Gonzalez,5 
Naveed Sarwar,5 Kamalram Thippu Jayaprakash   ,6,7 Gail Horan,6 
Feargus Hosking- Jervis,1 Natalia Klimowska- Nassar,1,8 Johanna Sukumar,1,8 
Tzveta Pokrovska,5 Dolan Basak,5 Angus Robinson,9 Mark Beresford,10 
Bhavan Rai,11 Stephen Mangar,5 Vincent Khoo,12 Tim Dudderidge,13 
Alison Falconer,5 Mathias Winkler,1,2 Verity Watson,3 Hashim Uddin Ahmed   1,2
To cite: Connor MJ, 
Genie MG, Gonzalez M, et al.  
Metastatic prostate cancer 
men’s attitudes towards 
treatment of the local tumour 
and metastasis evaluative 
research (IP5- MATTER): 
protocol for a prospective, 
multicentre discrete choice 
experiment study. BMJ Open 
2021;11:e048996. doi:10.1136/
bmjopen-2021-048996
 ► Prepublication history and 
additional supplemental material 
for this paper are available 
online. To view these files, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjopen- 2021- 048996).
VW and HUA are joint senior 
authors.
Received 14 January 2021
Accepted 21 October 2021
For numbered affiliations see 
end of article.
Correspondence to
Dr Martin John Connor;  
 m. connor@ imperial. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY. 
Published by BMJ.
ABSTRACT
Introduction Systemic therapy with androgen deprivation 
therapy (ADT) and intensification with agents such as 
docetaxel, abiraterone acetate and enzalutamide has 
resulted in improved overall survival in men with de novo 
synchronous metastatic hormone- sensitive prostate 
cancer (mHSPC). Novel local cytoreductive treatments and 
metastasis- directed therapy are now being evaluated. 
Such interventions may provide added survival benefit 
or delay the requirement for further systemic agents 
and associated toxicity but can confer additional harm. 
Understanding men’s preferences for treatment options in 
this disease state is crucial for patients, clinicians, carers 
and future healthcare service providers.
Methods Using a prospective, multicentre discrete choice 
experiment (DCE), we aim to determine the attributes 
associated with treatment that are most important to men 
with mHSPC. Furthermore, we plan to determine men’s 
preferences for, and trade- offs between, the attributes 
(survival and side effects) of different treatment options 
including systemic therapy, local cytoreductive approaches 
(external beam radiotherapy, cytoreductive radical 
prostatectomy or minimally invasive ablative therapy) 
and metastases- directed therapies (metastasectomy or 
stereotactic ablative body radiotherapy). All men with newly 
diagnosed mHSPC within 4 months of commencing ADT 
and WHO performance status 0–2 are eligible. Men who 
have previously consented to a cytoreductive treatment or 
have developed castrate- resistant disease will be excluded. 
This study includes a qualitative analysis component, 
with patients (n=15) and healthcare professionals (n=5), 
to identify and define the key attributes associated with 
treatment options that would warrant trade- off evaluation 
in a DCE. The main phase component planned recruitment 
is 300 patients over 1 year, commencing in January 2021, 
with planned study completion in March 2022.
Ethics and dissemination Ethical approval was obtained 
from the Health Research Authority East of England, 
Cambridgeshire and Hertfordshire Research Ethics 
Committee (Reference: 20/EE/0194). Project information 
will be reported on the publicly available Imperial College 
London website and the Heath Economics Research 
Unit (HERU website including the HERU Blog). We will 
use the social media accounts of IP5- MATTER, Imperial 
Prostate London, HERU and the individual researchers to 
disseminate key findings following publication. Findings 
from the study will be presented at national/international 
conferences and peer- reviewed journals. Authorship 
policy will follow the recommendations of the International 
Committee of Medical Journal Editors.
Trial registration number NCT04590976.
Strengths and limitations of this study
 ► IP5- MATTER will be the first multicentre discrete 
choice experiment conducted to evaluate men’s 
treatment preferences for local cytoreductive and 
metastasis- directed therapy in metastatic hormone- 
sensitive prostate cancer (mHSPC).
 ► The study will explore preference heterogeneity ac-
cording to the patients’ personal characteristics.
 ► This is the first study to determine if men with 
mHSPC are willing to accept the potential effect siz-
es that are reported in randomised studies.
 ► It is not feasible to incorporate all factors that may 
affect patients’ treatment preferences (eg, impact of 
hospital visits; the impact of drug effectiveness on 
disease progression).
 ► This study will be undertaken in the UK and may not 
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INTRODUCTION
The number of men diagnosed with prostate cancer each 
year in the UK is reported to be 47 000.1 In this cohort, 
it is estimated that 4500 men will have a diagnosis of de 
novo synchronous metastatic hormone- sensitive prostate 
cancer (mHSPC) at index presentation.1 The mainstay 
of treatment for such men has been hormonal castration 
with androgen deprivation therapy (ADT) alone. In isola-
tion, this treatment modality results in the emergence of 
a castrate- resistant state within a median of 11–18 months 
that restricts overall survival (OS) to 3.5 years.2 3
Recent advances with using ADT in combination with 
docetaxel or novel anti- androgens (eg, enzalutamide, 
abiraterone acetate, apalutamide) at diagnosis have led to 
a rise in the median OS to 4.8 years.3–9 Current research 
is considering the role of local cytoreductive approaches 
(cytoreductive radical prostatectomy, external beam 
radiotherapy or minimally invasive ablative therapy) 
and metastasis- directed interventions (predominantly, 
surgical metastatectomy or stereotactic ablative body 
radiotherapy (SABR)) with a view to acquiring further 
oncological benefit in this setting.1 10–18
Research into the role of local cytoreductive and 
metastasis- directed interventions has, in part, been prop-
agated by the emergence of the principle of an ‘oligo- 
metastatic’ state.19 In this context, men are hypothesised 
to harbour a favourable clinically defined, low disease 
burden that lies between ‘locally advanced’ and ‘poly- 
metastatic’ disease.19–21 Early randomised data suggest 
that men who exhibit such disease may gain the most 
benefit from additional cytoreductive interventions.10 22
These interventions offer potential overall and 
progression- free survival benefits. Furthermore, they may 
allow second- line systemic agents and their associated 
toxicities to be avoided or deferred. However, we currently 
understand very little about men’s treatment preferences 
and the decision- making process in this emerging treat-
ment paradigm.23
The IP5- MATTER study will use a discrete choice 
experiment (DCE) to determine men’s preferences 
for, and trade- offs between, the attributes (survival and 
side- effects) of different treatment options for mHSPC 
including systemic therapy, local cytoreductive and 
metastases- directed therapies.
Discrete choice experiment
A DCE is a survey method that is related to ‘conjoint 
analysis’.24 25 A DCE was selected as the method for this 
study as it allows the researcher to calculate the trade- offs 
that patients make between specific treatment options.26 
The trade- off in IP5- MATTER is whether a man is willing 
to accept the disadvantages to himself (ie, side effects, 
risk, visits to hospitals) with an extra treatment(s) in 
exchange for potential survival or cancer progression- 
free survival benefits. This is also termed the ‘marginal 
rate of substitution’.26
In the IP5- MATTER study, patients will be presented 
with hypothetical treatment scenarios.26 Each scenario 
will be described using a set of ‘attributes’ associated with 
each treatment for example, treatment modality, urine 
incontinence, fatigue, loss of erections, length of time 
until cancer starts to grow again, length of survival after 
diagnosis. Each treatment scenario will be associated with 
a realisation or level for each attribute. For instance, in a 
hypothetical treatment the urine incontinence attribute 
may take the value of 10% or 1 in 10 men, that is, of 100 
men who have the hypothetical treatment 1 in 10 will 
experience urine incontinence.
The attributes and levels will be combined into hypo-
thetical treatment scenarios and these will be grouped 
into treatment choice sets using experimental design 
theory. In essence, the patient will be asked to ‘choose’ 
between two treatments A or B in a choice set.
Each patient will be asked to complete several choice 
sets each containing different pairs of treatments. Each 
choice set will vary the levels of the attributes in a system-
atic way that allows the researcher to identify how the 
different realisations of the attributes affects the patients’ 
choices (figure 1). We will include up to 12 choices per 
patient.24 25
Previous DCEs in prostate cancer
A number of DCE studies have previously been completed 
in the field of non- metastatic prostate cancer, metastatic 
castrate- resistant prostate cancer (mCRPC) and mHSPC 
suitable to elicit patients’ treatment preferences.27–31
Non-metastatic prostate cancer
Sculpher et al undertook the first prostate cancer DCE in 
129 men in the UK with non- metastatic prostate cancer 
(T1 or T2).31 The primary focus was to evaluate side 
effects of various ADT options. The group reported men 
were willing to forgo up to 3 months of life expectancy to 
avoid limitations in physical energy.31
The recent COMPARE (COMparing treatment options 
for ProstAte cancer) multicentre study focused on 650 
men with newly diagnosed localised non- metastatic pros-
tate cancer (NCT01177865).32 Watson and colleagues 
identified that patients’ preferences for attributes for 
treatment were, in order: survival, no incontinence, not 
needing further treatment and maintaining an erection. 
Interestingly, men were willing to trade 0.68% absolute 
survival for a 1% absolute improvement in urinary func-
tion and 0.28% absolute survival for 1% absolute improve-
ment in maintaining erections.32
Furthermore, King and colleagues in a study of 357 
men with localised prostate cancer, who had undergone 
either radical therapy or commenced ADT, found men 
were similarly willing to trade- off 6 months of survival 
if they could avoid erectile dysfunction and approxi-
mately 13 months of survival if they could avoid urinary 
incontinence.28
Finally, in a study of 110 men with early prostate 
cancer, as well as their treating urologist, conducted by 
de Bekker- Grob and colleagues it was reported that while 
urinary incontinence was a concern among both patient 
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Figure 1 Example choice task. Example choice task for this study that is subject to change following the completion of Phase 
I and Phase II.
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and clinician, the risk of erectile dysfunction secondary 
to radiotherapy was solely valued by the clinician alone.27
Metastatic castrate-resistant prostate cancer
In the mCRPC setting, Eliasson and colleagues study 285 
men with mCRPC from three countries (Germany, France 
and the UK).30 The group reported that lower fatigue 
(OR, 1.365 (95% CI: 1.219 to 1.528)), and fewer addi-
tional hospital visits (OR, 1.245 (95% CI: 1.111 to 1.397)) 
were the most important factors affecting any treatment 
choice.30
Furthermore, Uemura and colleagues studied 133 
Japanese men with mCRPC to demonstrate that fatigue 
(relative importance (RI)=24.9% (95% CI: 24.7 to 25.1)) 
was the most important attribute.33 This was followed by 
a reduction in the risk of bone pain (RI=23.2% (95% CI: 
23.0 to 23.5)). The authors concluded that men were 
more concerned by quality- of- life secondary to side effects 
than any potential extension in survival.33
Metastatic hormone-sensitive prostate cancer
A single DCE in mHSPC has been performed by de Freitas 
and colleagues on a mixed cohort of 152 men, of which a 
minority (45/152; 29.6%) had mHSPC. The group eval-
uated docetaxel or abiraterone acetate in combination 
with ADT. Within the mHSPC subgroup, the primary 
ranked attribute was drug effectiveness on survival (rela-
tive attribute importance (RAI)=9.08), followed by pain 
control (RAI=6.37). Of note, men in this cohort were 
least concerned about method of treatment delivery 
(RAI=1.51).29
In summary, to our knowledge, no studies have under-
taken a DCE to elicit men’s preferences for systemic 
therapy in combination with either local cytoreductive 
and/or metastasis- directed treatments. The aforemen-
tioned, DCE studies in prostate cancer (non- metastatic, 
metastatic castrate- resistant and mHSPC) have predomi-
nantly highlighted patients’ preferences in the context of 
being offered established systemic therapy options and a 
select number of bone- targeted agents.
The IP5- MATTER study is a multicentre DCE designed 
to evaluate novel treatments (cytoreductive prostatectomy, 
external beam radiotherapy, minimally invasive ablative 
therapy and SABR) in addition to systemic therapy for the 
first time. To appropriately invest in emerging cytoreduc-
tive prostate and metastasis- directed treatments options 
that are most acceptable to such patients, we believe that 
an attempt to formalise our understanding of the trade- 
offs between oncological benefits and risks in this cohort 
of patients should be performed.
Study hypothesis
The null hypothesis (H0) is that men with de novo synchro-
nous hormone- sensitive metastatic prostate cancer will 
accept the complications and side effects associated with 
combined systemic and cytoreductive local prostate and/
or metastasis- directed therapy for any potential oncolog-
ical benefit.
The scientific hypothesis (H1) is that men with de 
novo synchronous hormone- sensitive metastatic prostate 
cancer may not accept the complications and risk of side 
effects associated with cytoreductive local prostate and/
or metastasis- directed therapy for any potential oncolog-
ical benefit.
Patient and public involvement
A patient involvement interview was held with two 
patients who had metastatic prostate cancer to deter-
mine initial patient acceptability of the study. The inte-
grated qualitative component of this study (Phases 1 
and 2) incorporates patient involvement. A patient and 
public involvement representative was present during the 
HRA REC assessment. This representative will continue 
to be involved throughout the duration of the study. 
This will include the Trial Management Group. Further-
more, other patients that are not involved directly in this 




IP5- MATTER will be performed at sites within the UK. 
This will be a cross- sectional questionnaire study. The 
initial qualitative phase (Phase 1) will involve semistruc-
tured interviews with (up to 5) clinician members of the 
multidisciplinary or tumour board meeting and (up to 5) 
patients who have had a diagnosis of mHSPC, to identify 
and define the key attributes associated with treatment 
options that would warrant trade- off evaluation. These 
will be used to create the first version of the questionnaire 
(Phase 1).26
Interviews with participants will be audiorecorded and 
transcribed verbatim. These will be destroyed on tran-
scription or within 2 months (whichever occurs earliest). 
Transcripts will be analysed using an inductive thematic 
analysis by at least two researchers. Inductive thematic 
analysis will be performed as described by Nowell and 
colleagues six- step iterative process.34 Researchers will 
(1) familiarise themselves with the data (eg, document 
potential themes/codes), (2) generate initial codes (eg, 
reflective journaling), (3) search for themes (eg, triangu-
lation of data), (4) review themes (eg, test for referential 
adequacy to raw data), (5) define themes and name and 
(6) produce a final report.34 The responses and sugges-
tions from the interviews will be used to develop the 
questionnaire in order to ensure that (1) any attribute or 
levels that do not seem appropriate are removed or modi-
fied; (2) any additional attributes or levels that are not in 
the questionnaire are included; (3) the questionnaire is 
understandable and (4) any complex treatment informa-
tion is explained in a accessible manner.26
In the DCE questionnaire, the attributes will be 
combined into different hypothetical scenarios that will 
be presented to men in the form of a treatment choice. 
The hypothetical scenarios included in the questionnaire 
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will be selected using experimental design theory. These 
attributes and levels will be combined to create treatment 
scenarios and paired into choice sets of two scenarios. We 
will use NGENE software (ChoiceMetrics) to generate a 
36 choice tasks D- efficient design with non- informative 
(null) priors and allowing estimation of non- linear effects 
of attributes.35 The design is based on the main effects 
only (ie, without interactions). The 36 choice tasks will be 
split into three blocks of 12 tasks to reduce respondent 
burden. Respondents will be allocated to one of the three 
blocks. Risk attributes will be presented using icon arrays, 
ratios and percentages to ease comprehension (figure 1) 
shows an example choice task. The questionnaire will 
be trialled on a different group of up to 10 men using a 
semistructured ‘Think Aloud’ interview and any further 
changes made to create the final version of the DCE ques-
tionnaire (Phase 2).36 The final survey instrument will 
also collect information on patients’ characteristics (eg, 
age, education).
This final questionnaire will then be used in the main 
phase of the study in 300 men across a number of UK trial 
sites over 12 months (Phase 3). The DCE questionnaire 
will be given to the participants to fill in, either directly 
following a face- to- face hospital clinic appointment or in 
their own home. For the electronic version of the survey, 
REDCap software will be used, with tablets available 
following a face- to- face hospital clinic appointment where 
required.
Study population
Men diagnosed with de novo synchronous mHSPC who 




 ► Diagnosed with mHSPC within 4 months of screening 
visit.
 ► WHO performance status 0–2.
Exclusion criteria
 ► Castrate- resistant metastatic prostate cancer.
 ► Patient has consented to a form of local cytoreductive 
treatment to the prostate.
 ► Patient has consented to a form of metastasis- directed 
therapy.
Identification of patients and consent
All men diagnosed with prostate cancer discussed at the 
multidisciplinary team (MDT) meeting (or a tumour 
board) as well as any man meeting the eligibility criteria 
prior to the MDT meeting will be identified for screening. 
Members of the MDT will identify patients suitable for 
IP5- MATTER. The treating clinicians will mention the 
study and the local research nurses, research fellows, clin-
ical trial coordinators, clinical trial practitioners or the 
treating clinicians will then approach the patient if they 
are interested.
Patients with confirmed metastatic prostate cancer 
and who satisfy the entry criteria will be approached for 
study enrolment. Patients can be included even if they 
have already commenced ADT, chemotherapy or an alter-
native hormonal agent as part of their standard of care. 
They will be provided with a patient information sheet 
(PIS) and as much time as they might need to consider 
whether or not they wish to participate (minimum 24 
hours).
Patients already aware of their diagnosis can be 
approached by telephone to enquire as to their interest 
in the study so that a PIS can be sent out by email or post 
prior to a clinical visit.
In the qualitative phases (Phases 1 and 2), patients who 
wish to participate after reading the PIS will be given a 
date for the semistructure interview (face- to- face or using 
audio- visual software). In the main Phase 3 component, 
patients who meet the eligibility criteria and are willing to 
participate will be given the questionnaire to fill in their 
own time either in the face- to- face or virtual hospital 
clinic or in their own home. Remote informed consent 
can be undertaken with the assistance of a telephone or 
audio- visual software, determined by local availability and 
protocol. An electronic method (in- built REDCap e- con-
sent form mirroring paper version with ‘advanced elec-
tronic signature’ using a smartphone, tablet, computer) 
will enable remote informed consent in accordance with 
HRA- MHRA e- consent guidance (2018).37 Informed 
consent will be signed before implementation of any 
study- related procedure.
Randomisation
No randomisation is required for this study.
Study outcome measures
Primary outcomes
 ► To determine the attributes associated with treatment 
that are most important to men with mHSPC.
 ► To determine men’s preferences for, and trade- offs 
between, the attributes (survival and side effects) of 
different treatment options in metastatic prostate 
cancer including systemic therapy, local cytoreductive 
and metastases- directed therapies.
Secondary outcomes
 ► To inform treatment pathways that are being devel-
oped nationally and internationally following 
randomised trials that are being conducted to eval-
uate these questions.
 ► The effect size from these studies can be used with our 
IP5- MATTER study to determine if, on average, men 
are willing to accept the potential effect sizes that are 
demonstrated in trials.
Study visits
 ► Phase 1 or 2: single- visit for semistructured interview 
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 ► Phase 3 (main study): single- visit completion of the 
electronic DCE during a routine hospital visit or at 
patient’s own home (table 1).
Follow-up
There is no planned follow- up for this study.
Sample size calculation and statistical analyses
Sample size and power considerations
IP5- MATTER trial sample size is set at 300. This is based 
on the premise that the precision of DCE parameter 
estimates improves until a sample size of 300 and then 
further gains in precision are small, according to the 
sampling strategy recommendations set by the Interna-
tional Society for Pharmacoeconomics and Outcomes 
Research Good Research Practices for Conjoint Analysis 
Task Force (2011).24
Planned recruitment rate
We are aware from the IP2- ATLANTA trial that centres 
have approximately three men diagnosed with meta-
static prostate cancer per month.12 38 The initial qualita-
tive phase will focus on the Northwest London regional 
cancer network (three hospitals) and take 6 weeks to 
complete. Full phase recruitment is based on 300 patients 
across 30 sites recruiting a minimum of 10 patients per 
year or about one patient per month. This is an esti-
mated recruitment rate of 26%. Our previous DCEs (ie, 
COMPARE) had an acceptance rate of over 50%.32
Statistical analysis
Responses from the DCE will be analysed using multino-
mial logit (MNL) regression techniques that allow for 
multiple observations from each respondent and pref-
erence differences across respondents.26 32 This will be 
used to understand treatment preferences and trade- offs 
made by patients when considering treatment options of 
mHSPC. In the MNL analysis, the functional form is spec-
ified as:
 Untj = βXntj + εntj 
which represents the utility of option j in choice task 
t for patient n, where  Xntj  is a vector of variables repre-
senting the levels of the treatment presented in option 
j,  β  is a vector of utility weights associated with each 
attribute and  εntj  is the error term. In the analysis, we will 
assume that patients gain utility (welfare) from treatment 
and the amount of welfare depends on the attributes and 
levels of the treatment. We assume that in each choice set 
patients choose the treatment that would bring them the 
highest welfare.
From the results of the DCE, it is possible to estimate 
the RI of attributes and the trade- offs that individuals are 
willing to make between attributes of a treatment. These 
trade- offs are how much of one attribute respondents are 
willing to sacrifice for improvements in another.26
In this case, we can explore how much life expectancy 
patients must gain before they are willing to accept treat-
ment side effects. Further, based on the regression results, 
we can calculate whether the attribute had a positive or 
negative effect on respondent utility, and the RI of a unit 
change in each attribute when respondents are choosing 
between treatments. We can also calculate the trade- offs 
that respondents make between treatment attributes 
when making choices, which is represented by the ratio 
of the coefficients.32
Additionally, we will explore observed preference 
heterogeneity according to patients’ characteristics. The 
observed characteristics will be analysed by interacting 
them with the attributes in the MNL model specifications.
Data collection
The principal means of data collection from partici-
pants will be electronic data capture using the web- based 
REDCap generated platform, provided by the Sponsor. 
All eCRFs will be completed using de- identified data.
Data monitoring and archiving
On two occasion per year, a combined independent data 
monitoring and trial steering committee will meet. All 
trial documentation will be archived for a minimum of 10 
years following the completion of the study.
Trial funding, organisation and administration
IP5- MATTER was approved by Health Research Authority 
East of England, Cambridgeshire and Hertfordshire 
Research Ethics Committee (20/EE/0194). The study is 
a joint collaboration between Imperial College London 
and Health Economic Research Unit (HERU), University 
of Aberdeen. This study is funded by the Wellcome Trust 
(204998/Z/16/Z) and University College London Hospi-
tals (UCLH) Charity (P83624/1348).
The study will be monitored periodically by trial 
monitors to assess progress and verify adherence to the 
protocol, ICH GCP E6 guidelines and other national/
international requirements and to review the complete-
ness, accuracy and consistency of the data (online supple-
mental material). The study may be subject to inspection 
and audit by regulatory bodies to ensure adherence to 
GCP and the UK Policy Framework for Health and Social 
Care Research.
Table 1 Visit schedule
IP5- MATTER
Visit Screening Visit 1
Week 0 0
Informed consent X
Inclusion and exclusion X
Demographics X
Medical history X
Study intervention: discrete choice 
experiment
X
This study does not have a follow- up visit.
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DISCUSSION
IP5- MATTER is a multicentre, prospective DCE in men 
with a new diagnosis of de novo synchronous mHSPC. 
This is the first DCE, to the author’s knowledge, that 
evaluates men’s treatment preferences for local cytore-
ductive and metastasis- directed therapy following such a 
diagnosis.
This study will determine men’s preferences for, and 
trade- offs between, the attributes (survival and side 
effects) of different treatment options in metastatic pros-
tate cancer including systemic therapy, local cytoreduc-
tive and metastases- directed therapies.
When taken collectively, it is expected that the results 
will be used to determine if, on average, men are willing 
to accept the potential effect sizes that are reported in 
current and future randomised studies. This will have 
wide- reaching implications on the investment in, and 
provision of, specific treatment options proposed for 
integration into the current standard of care treatment 
pathways for men with mHSPC.
Furthermore, it is possible that once such treatment 
pathways are established the findings from this DCE may 
be integrated into further work towards the creation of 
a decision treatment aid (DAT) for men with mHSPC. 
There is residual uncertainty in the role of DCE’s in the 
development of such DATs.39 However, this method-
ology is currently being explored in parallel to this study 
in localised prostate cancer and other benign surgical 
settings, and if proven IP5- MATTER may offer utility in 
the development in any future DAT for this cohort.40 41
CONCLUSION
IP5- MATTER answers important questions relating to 
men’s decision- making in relation to local cytoreductive 
and metastasis- directed treatments following a new diag-
nosis of mHSPC.
TRIAL STATUS
IP5- MATTER is opened to recruitment in 30 centres 
in England, Wales and Scotland in February 2022 and 
planned recruitment completed by February 2022 and 
study completion in April 2022.
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